2-chloroethyl pivalate | 51479-37-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-chloroethyl pivalate
• 英文别名: chloroethyl pivalate；Propanoic acid, 2,2-dimethyl-, 2-chloroethyl ester；2-chloroethyl 2,2-dimethylpropanoate
• CAS: 51479-37-9
• 化学式: C₇H₁₃ClO₂
• mdl: MFCD19233722
• 分子量: 164.632
• InChiKey: SIUTWYZMSNPSIO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloroethyl pivalate 、 三甲胺 生成 2-pivaloyloxyethyltrimethylammonium chloride
  参考文献：
  名称：

  Sevcik, Stanislav; Pradny, Martin, Collection of Czechoslovak Chemical Communications, 1986, vol. 51, # 1, p. 206 - 214

  摘要：

  DOI：

文献信息

• [EN] VLA-4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE VLA-4
  申请人：MERCK & CO INC

  公开号：WO2005087760A1

  公开（公告）日：2005-09-22

  Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn’s disease, multiple sclerosis, asthma, and rheumatoid arthritis.

  公式I的化合物是VLA-4的拮抗剂，因此在抑制或预防细胞粘附和细胞粘附介导的病理过程中非常有用。这些化合物可以制成药物组合物，并适用于治疗炎症性肠病，包括溃疡性结肠炎和克罗恩病，多发性硬化症，哮喘和类风湿性关节炎。
• [EN] MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY<br/>[FR] PROMÉDICAMENTS DE MÉBENDAZOLE À SOLUBILITÉ ET BIODISPONIBILITÉ ORALE AMÉLIORÉES
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2019157338A1

  公开（公告）日：2019-08-15

  Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.

  甲苯咪唑的前药及其在治疗疾病、紊乱或障碍，包括癌症中的使用方法被披露。
• Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same
  申请人：Kaken Pharmaceutical Co., Ltd.

  公开号：EP0103265A2

  公开（公告）日：1984-03-21

  Biphenylylpropionic acid derivatives of the formula: wherein R is an alkylcarbonyloxyalkyl group or an alkenylcarbonyloxyalkyl group having the formula: wherein R1 is hydrogen atom or a lower alkyl group having 1 to 5 carbon atoms, R2 is an alkyl group having 1 to 15 carbon atoms or an alkenyl group having 2 to 8 carbon atoms, and m is 0 or an integer of 1, provided that when R1 is a lower alkyl group, m is 0, or a lactone having the formula: wherein R3 and R4 are hydrogen atom or a lower alkyl group having 1 to 2 carbon atoms, and n is an integer of 1 or 2. The compounds have excellent anti-inflammatory, analgesic and antipyretic activities. Moreover, the compounds have no irritation, rapid and long acting and high safety margin.

  公式如下的双苯基丙酸衍生物： 其中R是具有以下式子的烷基羧酸氧烷基或烯基羧酸氧烷基： 其中R1是氢原子或具有1到5个碳原子的低烷基，R2是具有1到15个碳原子的烷基或具有2到8个碳原子的烯基，m为0或1的整数，但当R1为低烷基时，m为0，或具有以下式子的内酯： 其中R3和R4是氢原子或具有1到2个碳原子的低烷基，n为1或2的整数。这些化合物具有出色的抗炎、镇痛和退烧活性。此外，这些化合物无刺激性，作用迅速且持久，安全性高。
• Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment
  申请人：Patel Vithalbhai Mahesh

  公开号：US20080044466A1

  公开（公告）日：2008-02-21

  The present invention relates to optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof.

  本发明涉及光学纯的S-(−)-苯并喹啉羧酸、其衍生物、盐、伪多晶形、多晶形和水合物，基本上不含它们的R-(+)-异构体，以及制备光学纯的S-(−)-苯并喹啉羧酸、其衍生物、盐、伪多晶形、多晶形和水合物的过程，基本上不含它们的R-(+)-异构体，并且涉及包含S-(−)-苯并喹啉羧酸、其衍生物、盐、伪多晶形、多晶形和水合物的制药组合物。
• Vla-4 antagonists
  申请人：Hagmann K. William

  公开号：US20070179190A1

  公开（公告）日：2007-08-02

  Compounds of Formula I are antagonists of VLA-4, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of inflammatory bowel disease including ulcerative colitis and Crohn's disease, multiple sclerosis, asthma, and rheumatoid arthritis.

  公式I的化合物是VLA-4的拮抗剂，因此在抑制或预防细胞粘附和细胞粘附介导的病理方面非常有用。这些化合物可以制成药物组合物，并适用于治疗炎症性肠病，包括溃疡性结肠炎和克罗恩病、多发性硬化症、哮喘和类风湿性关节炎。